Posts filed under: Dental Biomaterials

This market’s value is expected to continue growing, demonstrating similar growth patterns in each of the resorbable and non-resorbable solutions. Nonetheless, market growth is threatened by increased competition. ...
Continue Reading →
Method offers pathway for improving patient outcomes after spinal fusion surgery...
Continue Reading →
Overall, the U.S. market for dental bone graft substitutes and other biomaterials is expected to increase to over $530 million by 2023...
Continue Reading →
Glidewell Laboratories recently announced the availability of a new line of bone grafting products, to be sold under the Newport Biologics™ brand name, featuring allograft and alloplast bone graft options....
Continue Reading →
FDA Safety Communication: Recombinant proteins and synthetic peptides bone graft substitutes are not approved for any use in patients under the age of 18....
Continue Reading →

Thank you!

CLOSE

Login

Sign Up

Already have an account? Sign in

×